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BACKGROUND: We set out to examine the activity of γ-glutamyltranspeptidase (GGT) in lung cancer and the validity of γ-
glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) for intraoperative imaging of primary lung cancer.METHODS: GGT
activities andmRNAexpression levels of GGT1 (one of theGGT subtypes) in five human lung cancer cell lineswere examined
by fluorescence imaging and quantitative reverse transcription polymerase chain reaction. In vivo imaging of an orthotopic
A549 xenograftmodel in nudemicewas performed to confirm its applicability to intraoperative imaging. Furthermore, ex vivo
imaging of 73 specimens from lung cancer patients were performed and analyzed to calculate the sensitivity/specificity of
gGlu-HMRG for lung cancer diagnosis.RESULTS: GGT activities andmRNAexpression levels of GGT1 are diverse depending
on cell type; A549, H441, and H460 showed relatively high GGT activities and expression levels, whereas H82 and H226
showed lower values. In the in vivo mouse model study, tiny pleural dissemination and hilar/mediastinal lymph node
metastasis (less than1mmindiameter)wereclearlydetected15minutesafter topical applicationofgGlu-HMRG. In theexvivo
studyofspecimens frompatients, thesensitivityandspecificityofgGlu-HMRGwerecalculated tobe43.8%(32/73)and84.9%
(62/73), respectively.When limited to femalepatients, neversmokers, andadenocarcinomas, thesevalueswere78.9%(15/19)
and 73.7% (14/19), respectively.CONCLUSIONS: AlthoughGGT activity of lung cancer cells vary, gGlu-HMRGcan serve as an
intraoperative imaging tool to detect small foci of lung cancer when such cells have sufficient GGT activity.
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Lung cancer has become the leading cause of cancer-related death in
many countries, including Japan [1]. Even when state-of-the-art
diagnostic tools are used, it is challenging to detect and visualize
minute lung cancer cells, especially those only a few millimeters in
diameter. Recently, we reported an activatable fluorescence probe,
γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), which
can be used as an intraoperative imaging tool for visualizing cancers
less than 1 mm in diameter [2]. gGlu-HMRG is nonfluorescent but
can be converted to highly fluorescent hydroxymethyl rhodamine
green (HMRG) upon reaction with γ-glutamyltranspeptidase
(GGT). GGT has essential roles in glutathione and drug metabolism,
as well as in leukotriene catabolism, which is localized mainly to the
surface of living cells [3] and which is highly expressed in some
normal tissues such as the proximal tubules of the kidney and the
hepatic bile epithelium [4]. GGT is also involved in anticancer drug
resistance in cancer cells and acceleration of tumor proliferation
including a relation with the ras oncogene [4–8], and is highly
expressed in malignant ovarian tumor, breast cancer, carcinoma of the
thyroid, and lung cancer [9–11]. Therefore, in this study, we firstly
investigated the feasibility of gGlu-HMRG as an intraoperative
diagnostic tool for primary lung cancer.
Material and Methods
Activatable Fluorescence probe
gGlu-HMRG was used as an activatable fluorescence probe
targeting GGT [2]. A 10-mM DMSO stock solution of gGlu-HMRG
was prepared and diluted to the final concentration described in the
experimental section.
Cell Lines and Culture Conditions
A549 was purchased from Riken Cell Bank, and four human lung
cancer cell lines (H441, H460, H82, and H226) were purchased
from the American Type Culture Collection. A549 cells were
cultured in high-glucose Dulbecco’s modified Eagle’s medium
(Wako, #04429765) supplemented with 10% fetal bovine serum
(Gibco, #10437028) and 1% penicillin-streptomycin (Gibco,
#15070063), and H441, H460, H82, and H226 cells were cultured in
RPMI-1640medium (Gibco, #11875093) supplementedwith 10% fetal
bovine serum (Gibco, #10437028) and 1% penicillin-streptomycin
(Gibco, #15070063) at 37°C in a humidified incubator with 5% CO2.
Cell Lysate
Cell lysates of each cell line were prepared using CelLytic M
(Sigma-Aldrich, #2978) according to the manufacturer's instructions.
Lysate protein concentration was calculated by the Bradford assay.
RNA Interference
The lung cancer cell lines (A549, H460, H441, H82, and H226)
were transfected with 10 nM of GGT1 siRNA (siRNA1 and siRNA2)
designed to interfere with GGT1 mRNA expression or control siRNA
using Lipofectamine RNAiMAX transfection reagent (Invitrogen,
#13778030). GGT1 is one of the subtypes of GGT, and the sequence
of each siRNA was as follows: GGT1 siRNA1 sense: 5′-rCrArArCr
ArGrCrArCrCrArCrArCrGrArArArArGrC-3′, GGT1 siRNA1 anti-
sense: 5′-UUUUrCrGUrGUrGrGUrGrGUrGUUrGUrA-3′, GGT1
siRNA2 sense: 5′-rCrCrArArGrGrArArCrCUrGrACAACCATG-3′,
GGT1 siRNA2 antisense: 5′-TGGTTGUrCrArGrGUUrCrCUU
rGrGrArG-3′, control siRNA sense: 5′-rGUrArCrCrGrCrArCrGUrCrAUUrCrGUrAUrC-3′, control siRNA antisense: 5′-UrArCr
GrArAUrGrArCrGUrGrCrGrGUrArCrGU-3′. Transfected cells
were cultured for 2 days in an 8-well chamber slide (ibidi, #ib80826)
or a 10-cm dish and subsequently used for live-cell fluorescence imaging
or quantitative reverse transcription polymerase chain reaction
(qRT-PCR) analysis, respectively.
qRT-PCR analysis
Total mRNA of the lung cancer cell lines (A549, H460, H441,
H82, and H226) was extracted using TRIzol RNA Isolation Reagent
(Gibco, #10296028), and first-strand cDNAs were synthesized using
the PrimeScript II 1st strand cDNA Synthesis Kit (TAKARA,
#C6210A). qRT-PCR was performed with Light Cycler 480 System
II (Roche) in triplicate using a LightCycler 480 SYBR Green I Master
(Roche, #04707516001). Cycling conditions were as follows: 50°C
for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for
15 seconds, 60°C for 1 minute, and 72°C for 1 minute. The GGT1
mRNA expression level of each lung cancer cell line was measured and
normalized to HPRT1 mRNA expression level. The primer sequences
used were as follows: GGT1, forward: 5′-GTGTTCTGCCGGGAT
AGAAA-3′; GGT1, reverse: 5′-CAGGTCCTCAGCTGTCACAA-3′;
hHPRT1, forward: 5′-GTTCTTTGCTGACCTGCTGGAT-3′;
hHPRT1, reverse: 5′-CTTTTATGTCCCCCGTTGACTG-3′.
Animals
Female severe combined immunodeficiency disease mice (BALB/
cAjcl-nu/nu) were purchased from CLEA Japan, Inc. These mice had
been raised from birth in a specific pathogen-free environment. The mice
were 7 weeks old and weighed 20-25 g when the experiments started.
An orthotopic A549 xenograft model was developed in nude mice as
follows [12,13]: A549 cells were harvested and suspended (4 × 107 cells/ml)
in PBS (−) and mixed with the same volume of 10% Matrigel.
BALB/cAjcl-nu/nu mice were anesthetized by intraabdominal
injection of ketamine (2 mg/mouse) and xylazine (0.2 mg/mouse),
and a small skin incision, approximately 2 cm on the left chest wall, was
made. A total of 25 μl of the above-mentioned cell suspension was
directly injected into left lung with a 30-gauge needle attached to a 1-ml
syringe. The skin incisionwas closed with 4-0 nylon and observed until mice
woke up from the anesthesia. After 1-2 weeks of breeding, mice were
sacrificed and evaluated by the fluorescence imaging system. A total of 19
mice were used for in vivo imaging. All animal studies were approved by
Office for Life Science Research Ethics and Safety, The University of Tokyo.
In Vitro Fluorescence Imaging Study
Cultured in 8-well chamber slides (ibidi, #ib80826), fluorescence
images were captured before and 5, 10, and 30 minutes after probe
application (1 μM solution of gGlu-HMRG in Dulbecco’s modified
Eagle’s medium or RPMI) by confocal fluorescence microscopy SP5
(Leica Microsystems) at 37°C. The excitation and emission
wavelength was 488 nm and 500-600 nm, respectively.
Lung cancer cell lysates were mixed with 5.5 μMgGlu-HMRGwith
PBS (−) in a 96-well plate. The fluorescence intensity was measured in
triplicate before and 5, 10, 15, 20, 25, and 30 minutes after lysate
addition on an SH-8000 plate reader (Corona Electric). The
fluorescence intensity was standardized by lysate protein concentration.In Vivo Fluorescence Imaging Study of Mice
A 10-μM solution of gGlu-HMRG in PBS (−) was topically
dripped into the left thoracic cavity of the orthotopic A549 xenograft
Figure 1. Confocal fluorescence imaging of lung cancer cell lines loaded with 1 µM gGlu-HMRG. Images were captured before and 5, 10,
and 30 minutes after probe application. Images of cells loaded with 1 µM HMRG were captured after 30 minutes, serving as positive
controls. Strong fluorescence signals were observed after 30 minutes from A549, H460, and H441 cells, but not from H82 and H226 cells.
Scale bar represents 100 μm.
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were captured by fluorescence stereo microscopy (Leica M 165FC, Leica
Microsystems) at room temperature. Excitation and emission filters were
460-500 nm band pass and 510 nm long pass, respectively.Figure 2. Lysate assay and qRT-PCR of lung cancer cell lines. (A) Fluo
and 30 minutes after application of 5.5 µM gGlu-HMRG. Fluorescen
H441, but not in H82 and H226. Bar represents fluorescence intensit
levels of five lung cancer cell lines measured by qRT-PCR. hHPRT1 wa
higher relative GGT1 expression compared with that of H82 and H2
(A.U.) + standard deviation.Ex Vivo Fluorescence Imaging Study of Patient Specimens
A total of 73 specimens, including lung tumor and normal lung,
were obtained from the Department of Thoracic Surgery, Graduate
School of Medicine, The University of Tokyo (e-Table 1). All therescence intensity of lung cancer cell lysate before and 1, 5, 10, 20,
ce intensity increased gradually in the lysates of A549, H460, and
y (A.U.) + standard deviation. (B) Relative GGT1 mRNA expression
s used as a reference gene. A549, H460, and H441 had significantly
26 (P b .05-.01). Bar represents the relative GGT1 mRNA contents
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cancer fluorescence imaging study and the review of their medical
charts. The Research Review Board at our institution examined and
approved the research protocol in accordance with the Declaration of
Helsinki. Tumor stage was determined according to the seventh
edition of the TNM staging system of the International Union
Against Cancer, and histologic tumor type was assessed according to
the third edition of the World Health Organization classification
[14,15]. All gGlu-HMRG fluorescence imaging studies were
performed within 1-2 hours after lung resection. Images were
captured by Maestro in vivo imaging system (CRi Inc.) before and 5,
10, and 30 minutes after applying approximately 100 μl of 50 μM
gGlu-HMRG solution in PBS (−) to lung tumor and normal lungFigure 3. RNA interference targeted to GGT1. (A) Confocal fluoresce
GGT1 siRNA (siRNA 1 and siRNA 2) or control siRNA, followed by incu
100 μm. (B) Relative GGT1 mRNA expression level of lung cancer cell
siRNA measured by qRT-PCR. hHPRT1 was used as a reference gene
siRNA 1 and siRNA2 were significantly suppressed compared with t
contrast, there was no significant difference in GGT1mRNA contents
mRNA contents (A.U.) + standard deviation.specimens, respectively, at room temperature. The excitation and
emission wavelength was 445-490 nm and 515 nm long pass,
respectively. Regions of interest were drawn three times for both lung tumor
and normal lung, and the mean fluorescence intensity was calculated using
Maestro software. Increase in fluorescence intensity was defined by
subtracting initial fluorescence intensity from thatmeasured after 30minutes
of incubation with the probe. After the imaging experiment, specimens were
preserved in 10% formalin for hematoxylin and eosin staining.
Statistical Analysis
Statistical analysis was performed using JMP 11.0 pro (SAS Institute
Inc.). Sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), accuracy, and false-positive and -negative ratesnce imaging of lung cancer cell lines. Cells were transfected with
bation with 1 μM gGlu-HMRG for 30 minutes. Scale bar represents
lines transfected with GGT1 siRNA (siRNA1 and siRNA2) or control
. GGT1 mRNA contents of A549, H460, and H441 transfected with
hose transfected with control siRNA respectively (P b .001-.05). In
of H82 and H226 (P b .05, P= .20-.99). Bar represents relative GGT1
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chi-square tests and Student’s t tests were performed where applicable
and relevant. Differences were considered statistically significant when
the probability (P) value was b .05.
Results
In Vitro and In Cellulo Studies of GGT1 Activity
Live-cell fluorescence imaging using confocal fluorescence microscopy
revealed that the lung cancer cell lines had different GGT activity. After
incubating with 1 μM gGlu-HMRG solution, we observed a strong
fluorescence signal from A549, H460, andH441 cells in several minutes,
but not from H82 and H226 cells (Figure 1). The lysate assay also
demonstrated differences in GGT activity among lung cancer cell lines,
giving almost identical results as those obtained through live-cell
fluorescence imaging (Figure 2A). By qRT-PCR analysis, the relative
GGT1 mRNA expression levels of A549, H460, and H441 were
significantly higher to those of H82 andH226 (P b .05-.01) (Figure 2B).
Among several GGT subtypes, we focused on GGT1 because this
subtype is reported to be involved in both glutathione catabolism and
anticancer drug resistance, which was characterized by cancer cell [3].
RNA Interference Experiments Targeted to GGT1
In A549, H460, and H441 cells, we observed significantly reduced
fluorescence signal when cells were pretransfected with GGT1
siRNAs compared with those transfected with control siRNA. In
contrast, in H82 and H226 cells, there was no significant difference in
fluorescence signal intensity whether cells were transfected with GGT1
siRNAs or control siRNA (Figure 3A). We also confirmed that the relative
GGT1mRNA expression levels of A549, H460, andH441 cells transfected
with GGT1 siRNAs were significantly suppressed compared with thoseFigure 4. White light and fluorescence images of hilar and mediasti
orthotopic A549 xenograft model, captured by stereo fluorescence m
confirmed to be an aggregation of A549 lung cancer cells by hemat
image. (C) Merged image of white light and fluorescence. (D) Hema
staining of mediastinal lymph node. (F) Hematoxylin and eosin stainitransfected with control siRNA (P b .001), whereas those ofH82 andH226
cells transfected with GGT1 siRNAs were as low as those transfected with
control siRNA by qRT-PCR analysis (P b .05, P = 0.20–0.99) (Figure 3B).
In Vivo Imaging of the Orthotopic A549 Xenograft Model
Using white light imaging, it was difficult to recognize the minute
pleural dissemination and lymph node metastases, which were less than
2-3 mm in diameter. However, these lesions were clearly visualized 15
minutes after topical dripping of gGlu-HMRG (Figure 4, A–C).
Aggregation of A549 was ascertained by hematoxylin and eosin staining
of extracts from lung tumor, hilar and mediastinal lymph nodes, and
pleural dissemination, respectively (Figure 4, D–F).
Ex Vivo Imaging of Specimens from Lung Cancer Patients
In cases 1 and 2, we observed a gradual increase in fluorescence
in the lung tumor region compared with that in normal lung after
topical application of 50 μM gGlu-HMRG. We also confirmed
increasing fluorescence signal over 30 minutes, evidenced by data
from the intensity graph. In contrast, in case 3, the fluorescence
intensity in lung tumor and normal lung did not change much even
after 30 minutes post probe application (Figure 5, A and B). Cases 1
and 2 were confirmed histologically as adenocarcinoma, and case 3
was identified as squamous cell carcinoma. Analyzed by receiver operating
characteristic curves, the sensitivity and specificity of fluorescence imaging
for lung cancer were calculated to be 43.8% (32/73) and 84.9% (62/73),
respectively, and PPV, NPV, and accuracy were 74.4% (32/43), 60.2%
(62/103), and 64.4% (94/146), respectively (Figure 6, A and B). The
false-positive and -negative rates were 15.1% (11/73) and 56.2% (41/73),
respectively. On the basis of clinicopathological analysis, cancer in
females, never smokers, and cases of adenocarcinomaswere detectedmore
often by fluorescence imaging (P b .001-.05) (e-Figure 1).When limitingnal lymph node metastasis and pleural dissemination in a murine
icroscopy. Every lesion with strong fluorescence was pathologically
oxylin and eosin staining. (A) White light image. (B) Fluorescence
toxylin and eosin–stained lung tumor. (E) Hematoxylin and eosin
ng of pleural dissemination. Scale bar represents 100 μm.
Figure 5. Ex vivo fluorescence imaging of specimens from lung cancer patients. (A) White light and fluorescence images of lung cancer
specimens. A total of 50 µM gGlu-HMRG was applied to lung tumor and normal lung tissue, and images were captured before and 5, 10,
and 30minutes after by Maestro with appropriate exposure time. Fluorescence image at 540 nmwas extracted. Fluorescence intensity of
the lung tumor was increasing in case 1 and 2, but not in case 3. (B) Fluorescence intensity values of lung tumor and normal lung in case 1,
2, and 3 were calculated. Fluorescence intensity gradually increased in case 1 and 2, but not in case 3.
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adenocarcinomas (N = 19), the sensitivity and specificity were 78.9%
(15/19) and 73.7% (14/19), respectively, and PPV, NPV, and accuracy
were 78.9% (15/19), 73.7% (14/19), and 76.3% (29/38), respectively
(Figure 6, C and D). The false-positive and -negative rates were 26.3%
(5/19) and 21.1% (4/19), respectively.
Discussion
Lung cancer has become a leading cause of cancer-related death in Japan
[1]. To improve prognosis, many efforts have been made to develop
effective intraoperative diagnostic tools to visualize cancer cells with high
sensitivity [16]. For example, Zhang et al. reported that the
COX-2-specific fluorescence probe, ANQ-IMC-6, could visualize cancer
cells at the early stage [17]. Koyama et al. demonstrated that an optical
probe conjugated to HER2 antibody enabled detection of pulmonary
metastasis in in vivo imaging [18]. Clinically, five-aminolaevulinic acid
has beenwidely applied for imaging residual brain glioblastoma, colorectal
cancer, and pleural malignancy [19–22]. However, only limited studies
are available [23]. Apart from these probes, gGlu-HMRG is characterized
by an activatable cancer-specific fluorescence probe targeting GGT that
enables rapid and sensitive visualization of cancer cells with topical
application when cancer cells have sufficient GGT expression.This study is the first investigation for lung cancer imaging less
than 1 mm using gGlu-HMRG for the purpose of intraoperative
imaging. Unfortunately, sensitivity and specificity of lung cancer
imaging with gGlu-HMRG in our ex vivo experiment study were
limited to 43.8% and 84.9%, respectively. Hanigan et al.
demonstrated that 18 adenocarcinomas of 44 cases of lung cancer
(40.9%) had high GGT expression, evidenced by immunohisto-
chemical staining, which added support to our results [11]. Although
sensitivity was as low as about 50%, selecting the lung cancer cases
especially for females, never-smokers, and cases with adenocarcinoma,
sensitivity and specificity were raised up to 78.9% and 73.7%,
respectively. And more, if we will be able to confirm the availability
of gGlu-HMRG using preoperative biopsy specimen of a lung
cancer patient before operation, we could perform intraoperative lung
cancer fluorescence imaging without fail. Sensitivity must be more
improved to be nearly 90% to 100% when preoperative case selection
is possible.
Clinically, intraoperative application of gGlu-HMRG may be
feasible and advantageous for visualization of cancer cells, especially in
surgical margin or pleural cavity of lung cancer surgery. Limited
resection or wedge resection mainly by video-assisted thoracic surgery
has been recently on the rise [24–26]. One of the issues is locoregional
Figure 6. Increase in fluorescence intensity in lung tumor and normal lung after 30 minutes and the results of cutoff value, sensitivity, and
specificity of gGlu-HMRG for detection of lung cancer analyzed by receiver operating characteristic curves for all 73 cases and a subset of
19 patients comprising females, never-smokers, and patients with adenocarcinoma. Sensitivity and specificity for all cases were 43.8%
(32/73 cases) and 84.9% (62/73 cases), respectively. Limited to the 19 cases of females, never-smokers, and cases of adenocarcinoma,
the sensitivity and specificity were 78.9% (15/19 cases) and 73.7% (14/19 cases), respectively. AUC, area under curve.
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rate of locoregional recurrence has ranged between 1.1% and 17.2%
(median, 6.0%) [27–32]. And more, it is also challenging to detect
very small foci of pleural dissemination or carcinomatous pleuritis
that are macroscopically invisible [33]. In the current practical
method, a pathological examination for a surgical margin or pleural
lavage cytology is performed to detect a remnant tumor cell, taking
around 30 minutes. However, a surgeon could not detect the exact
location of a tumor cell intraoperatively. And even if five-
aminolaevulinic acid is used for a lung cancer patient with high
sensitivity, a tiny tumor within 1 mm in diameter could not be seen
[23]. In contrast, intraoperative fluorescence imaging with
gGlu-HMRG could be a simple and effective procedure to detect
small foci of cancer cells within 1 mm in diameter in several minutes if
a cancer cell has high GGT activity.
There are some limitations of gGlu-HMRG in practical use.
Because the wavelength of HMRG is around 500 nm, superficially
exposed cancer cells could be detected by fluorescence imaging with
topical gGlu-HMRG. Meanwhile, deeply located cancer would notbe visualized. It should also be mentioned that gGlu-HMRG was
nonspecifically activated in some lungs, leading to a false-positive rate
up to 15.1%. Because macrophages have some GGT activity [4], we
considered that lung tissue with accumulation of histiocytes may have
a possibility to exhibit increased fluorescence when exposed to
gGlu-HMRG (e-Figure 2). Same results were ascertained in three
cases including case 4. A cytotoxicity test and development of a
medical device for fluorescence imaging are also indispensable for
increasing the practical utility of gGlu-HMRG. Although several
challenges remain, this rapidly activatable fluorescence probe could be
of great value for general thoracic surgery.
Conclusions
We have validated the utility of gGlu-HMRG as an intraoperative rapid
imaging tool. We believe that detecting pleural dissemination, small
mediastinal lymph nodemetastasis, or other small foci of lung cancer cells
should greatly help surgeons to improve the prognosis in near future.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.03.007.
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